John Leonard, M.D., has been named president and chief executive officer, Intellia Therapeutics, Inc., effective January 1, 2018. Intellia is a genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology. Dr. Leonard succeeds Nessan Bermingham, Ph.D., Intellia’s founding president, who is returning to the venture capital industry. Dr. Leonard will lead the company as it progresses toward clinical development, leveraging his experience in successfully developin...